Talphera (NASDAQ:TLPH) Upgraded by Zacks Research to Hold Rating

Talphera (NASDAQ:TLPH) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

TLPH has been the topic of a number of other reports. HC Wainwright initiated coverage on Talphera in a research report on Friday, June 5th. They set a “buy” rating and a $3.00 price target on the stock. Westpark Capital initiated coverage on Talphera in a research report on Thursday, April 30th. They set a “buy” rating and a $3.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.00.

Talphera Trading Down 3.7%

TLPH stock opened at $0.82 on Monday. Talphera has a 1-year low of $0.38 and a 1-year high of $1.57. The firm has a market cap of $42.33 million, a P/E ratio of -2.63 and a beta of 0.76. The business’s 50 day moving average is $0.81 and its 200-day moving average is $0.94.

Talphera (NASDAQ:TLPH) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. Sell-side analysts forecast that Talphera will post -0.26 EPS for the current year.

Insider Buying and Selling

In other news, CEO Vincent J. Angotti acquired 213,310 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were purchased at an average cost of $0.59 per share, for a total transaction of $125,852.90. Following the transaction, the chief executive officer owned 800,705 shares of the company’s stock, valued at approximately $472,415.95. This represents a 36.31% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Group One Trading LLC boosted its position in Talphera by 3,224.0% in the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after buying an additional 29,500 shares during the last quarter. Virtu Financial LLC bought a new position in Talphera in the 3rd quarter valued at $29,000. Mariner LLC boosted its position in Talphera by 132.0% in the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after buying an additional 33,000 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in Talphera in the 4th quarter valued at $42,000. Finally, Dauntless Investment Group LLC bought a new position in Talphera in the 3rd quarter valued at $89,000. 37.67% of the stock is currently owned by institutional investors.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.